Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical and clinical features of chronic granulomatous disease[J]. Medicine, 2000, 79(3): 170-200.
[2]
Walrand S, Valeix S, Rodriguez C, et al. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes[J]. Clin Chim Acta, 2003, 331(1-2): 103-110.
[3]
Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease report on a national registry of 368 patients[J]. Medicine, 2000, 79(3): 155-169.
Rothe G, Emmendorffer A, Oser A, et al. Flow cytometric measurement of the respiratory burst activity of phagocytes using dihydrorhodamine 123[J]. J Immunol Methods, 1991, 138(1): 133-135.
[7]
Vowells SJ, Fleisher TA, Malech HL. Testing for chronic granulomatous disease[J]. The Lancet, 1996, 347(9007): 1048.
[8]
Jirapongsananuruk O, Malech HL, Kuhns DB, et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay[J]. J Allergy Clin Immunol, 2003, 111(2): 374-379.
[9]
Crockard AD, Thompson JM, Boyd NA, et al. Diagnostic and carrier detection of chronic granulomatous disease in five families by flow cytometry[J]. Int Arch Allergy Immunol, 1997, 114(2): 144-152.
[10]
van Pelt LJ, van Zwieten R, Weening RS, et al. Limitations on the use of dihydrorhodamine 123 for flow cytometric analysis of the neutrophil respiratory burst[J]. J Immunological Methods, 1996, 191(2): 187-196.
[11]
Mauch L, Lun A, O'Gorman MR, et al. Chronic granulomatous disease and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD[J]. Clin Chem, 2007, 53(5): 890-896.
